The grades of four Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Johnson & Johnson (NYSE:JNJ) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, and Equity, JNJ also gets A’s. The stock has a dividend yield of 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Bristol-Myers Squibb Company (NYSE:BMY) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. The stock price has risen 6.5% over the past month, better than the 1.7% decrease the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BMY stock.
This week, Watson Pharmaceuticals (NYSE:WPI) pushes up from a B to an A rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This is a strong week for Repros Therapeutics (NASDAQ:RPRX). The company’s rating climbs to A from the previous week’s B. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.